

# Hongyun Zhao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9645165/publications.pdf>

Version: 2024-02-01

83  
papers

2,619  
citations

304602

22  
h-index

223716

46  
g-index

85  
all docs

85  
docs citations

85  
times ranked

4186  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reducing number of target lesions for RECIST1.1 to predict survivals in patients with advanced non-small-cell lung cancer undergoing anti-PD1/PD-L1 monotherapy. <i>Lung Cancer</i> , 2022, 165, 10-17.	0.9	1
2	Time to raise the bar: Transition rate of phase 1 programs on anticancer drugs. <i>Cancer Cell</i> , 2022, 40, 233-235.	7.7	3
3	Distinct Functional Metagenomic Markers Predict the Responsiveness to Anti-PD-1 Therapy in Chinese Non-Small Cell Lung Cancer Patients. <i>Frontiers in Oncology</i> , 2022, 12, 837525.	1.3	6
4	First-in-human phase I results of APG-2449, a novel FAK and third-generation ALK/ ROS1 tyrosine kinase inhibitor (TKI), in patients (pts) with second-generation TKI-resistant ALK/ROS1 non-small cell lung cancer (NSCLC) or mesothelioma. <i>Journal of Clinical Oncology</i> , 2022, 40, 9071-9071.	0.8	5
5	Updated study results of pelcitoclax (APG-1252) in combination with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2022, 40, 9116-9116.	0.8	0
6	FOXM1 Variant Contributes to Gefitinib Resistance via Activating Wnt/ $\beta$ -Catenin Signal Pathway in Patients with Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3770-3784.	3.2	12
7	Mendelian randomization study indicates lack of causal relationship between physical activity and lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 177-181.	1.2	8
8	Establishment and application of a predictive model for gefitinib-induced severe rash based on pharmacometabolomic profiling and polymorphisms of transporters in non-small cell lung cancer. <i>Translational Oncology</i> , 2021, 14, 100951.	1.7	9
9	Clinical Significance of Kinetics of Low-Density Lipoprotein Cholesterol and Its Prognostic Value in Limited Stage Small Cell Lung Cancer Patients. <i>Cancer Control</i> , 2021, 28, 107327482110282.	0.7	5
10	Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer. <i>Molecular Cancer</i> , 2021, 20, 37.	7.9	36
11	Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, e20214.		16
12	Therapeutic drug monitoring of docetaxel by pharmacokinetics and pharmacogenetics: A randomized clinical trial of AUC-guided dosing in nonsmall cell lung cancer. <i>Clinical and Translational Medicine</i> , 2021, 11, e354.	1.7	5
13	Afatinib as a Potential Therapeutic Option for Patients With NSCLC With EGFR G724S. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100193.	0.6	3
14	Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China. <i>Journal of Hematology and Oncology</i> , 2021, 14, 124.	6.9	12
15	Baseline and early changes in circulating Serum Amyloid A (SAA) predict survival outcomes in advanced non-small cell lung cancer patients treated with Anti-PD-1/PD-L1 monotherapy. <i>Lung Cancer</i> , 2021, 158, 1-8.	0.9	10
16	Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes. <i>Cancer Cell International</i> , 2021, 21, 458.	1.8	7
17	Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706). <i>Journal of Thoracic Oncology</i> , 2021, 16, 1533-1546.	0.5	64
18	Response to: The Role of Dual Inhibition of EGFR and Vascular EGF(R) in the Treatment of NSCLC With EGFR Mutation. <i>Journal of Thoracic Oncology</i> , 2021, 16, e72-e76.	0.5	0

#	ARTICLE	IF	CITATIONS
19	Response to "Limitations of the Hazard Ratio as a Summary Measure in Cancer Clinical Trials", <i>Journal of Thoracic Oncology</i> , 2021, 16, e87-e88.	0.5	0
20	Determinants of survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 therapy. <i>Annals of Translational Medicine</i> , 2021, 9, 1639-1639.	0.7	4
21	Emerging immunological strategies: recent advances and future directions. <i>Frontiers of Medicine</i> , 2021, 15, 805-828.	1.5	5
22	Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis. , 2020, 8, e001170.		28
23	PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 1258-1267.	1.3	47
24	Incidence and risk factors of second primary cancer after the initial primary human papillomavirus related neoplasms. <i>MedComm</i> , 2020, 1, 400-409.	3.1	3
25	Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2020, 3, e2015748.	2.8	36
26	Impact of prior cancer history on the overall survival of younger patients with lung cancer. <i>ESMO Open</i> , 2020, 5, e000608.	2.0	15
27	Combinatorial assessment of ctDNA release and mutational burden predicts anti-PD(L)1 therapy outcome in nonsmall-cell lung cancer. <i>Clinical and Translational Medicine</i> , 2020, 10, 331-336.	1.7	12
28	Anticancer drug R&D landscape in China. <i>Journal of Hematology and Oncology</i> , 2020, 13, 51.	6.9	6
29	Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer. <i>Clinical and Translational Medicine</i> , 2020, 10, e33.	1.7	13
30	KEYNOTE-032: A Randomized Phase I Study of Pembrolizumab in Chinese Patients with Advanced Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2020, 25, 650-e1145.	1.9	11
31	EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients. <i>Clinical and Translational Medicine</i> , 2020, 9, 17.	1.7	19
32	EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients. <i>Translational Lung Cancer Research</i> , 2020, 9, 471-483.	1.3	11
33	Anti-epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma. <i>Cancer Medicine</i> , 2020, 9, 1721-1732.	1.3	15
34	Clinical pharmacokinetics and drug exposure-toxicity correlation study of docetaxel based chemotherapy in Chinese head and neck cancer patients. <i>Annals of Translational Medicine</i> , 2020, 8, 236-236.	0.7	7
35	The preliminary efficacy and safety data of KN046 in patients failed on prior immune checkpoint inhibitors therapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3020-3020.	0.8	15
36	Phase Ia dose escalation of IBI318, a first-in-class bispecific anti-PD-1/PD-L1, in patients with advanced tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3062-3062.	0.8	4

#	ARTICLE	IF	CITATIONS
37	A phase Ib study of a novel c-MET, AXL and VEGFR-2 inhibitor ningetinib and gefitinib combination therapy in Chinese EGFR-TKI resistant NSCLC with T790M negative.. Journal of Clinical Oncology, 2020, 38, 9583-9583.	0.8	2
38	A phase I, dose-escalation and expansion study of TQ-B3139, a novel ALK TKI, in Chinese ALK or ROS1 positive advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, 9585-9585.	0.8	4
39	Myeloid cell leukemia-1 is an important predictor of survival and progression of small cell lung cancer. Annals of Translational Medicine, 2020, 8, 1589-1589.	0.7	1
40	Cause-specific death assessment of patients with stage I small-cell lung cancer: a competing risk analysis. Future Oncology, 2019, 15, 2479-2488.	1.1	7
41	The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma. Nature Communications, 2019, 10, 3108.	5.8	69
42	Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing. Molecular Cancer, 2019, 18, 7.	7.9	48
43	Education and lung cancer: a Mendelian randomization study. International Journal of Epidemiology, 2019, 48, 743-750.	0.9	73
44	Comparison of the Prognostic Value of Systemic Inflammation Response Markers in Small Cell Lung Cancer Patients. Journal of Cancer, 2019, 10, 1685-1692.	1.2	34
45	Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer. Clinical Cancer Research, 2019, 25, 5015-5026.	3.2	143
46	A Phase I/II Open-Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors. Oncologist, 2019, 24, 891-e431.	1.9	25
47	Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China. Oncologist, 2019, 24, S11-S20.	1.9	2
48	The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer. , 2019, 7, 98.		53
49	Docosapentaenoic acid and lung cancer risk: A Mendelian randomization study. Cancer Medicine, 2019, 8, 1817-1825.	1.3	10
50	Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591989165.	1.4	10
51	Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer. International Journal of Cancer, 2019, 144, 2854-2866.	2.3	10
52	Impact of prior cancer on outcomes in nasopharyngeal carcinoma. Annals of Translational Medicine, 2019, 7, 299-299.	0.7	8
53	Multi-targeted tyrosine kinase inhibitors as third-line regimen in advanced non-small cell lung cancer: a network meta-analysis. Annals of Translational Medicine, 2019, 7, 452-452.	0.7	9
54	Risk of second primary malignancy after non-small cell lung cancer: a competing risk nomogram based on the SEER database. Annals of Translational Medicine, 2019, 7, 439-439.	0.7	25

#	ARTICLE	IF	CITATIONS
55	The analysis of pharmacokinetic and pharmacogenomic impact on gefitinib efficacy in advanced non-small cell lung cancer patients: results from a prospective cohort study. <i>Annals of Translational Medicine</i> , 2019, 7, 806-806.	0.7	11
56	Modification of the tumor response threshold in patients of advanced non-small cell lung cancer treated with chemotherapy plus targeted agents: a pooled study from five clinical trials in one institution. <i>Annals of Translational Medicine</i> , 2019, 7, 253-253.	0.7	1
57	First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance. <i>Journal of Thoracic Oncology</i> , 2018, 13, 968-977.	0.5	50
58	Impact of prior cancer history on the overall survival of patients newly diagnosed with cancer: A pan-cancer analysis of the SEER database. <i>International Journal of Cancer</i> , 2018, 143, 1569-1577.	2.3	57
59	Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis. <i>Oncologist</i> , 2018, 23, 603-616.	1.9	17
60	Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. <i>Lancet Oncology</i> , The, 2018, 19, 1338-1350.	5.1	337
61	Development and validation of a UPLC-MS/MS method for quantification of osimertinib (AZD9291) and its metabolite AZ5104 in human plasma. <i>Biomedical Chromatography</i> , 2018, 32, e4365.	0.8	19
62	A large, single-center, real-world study of clinicopathological characteristics and treatment in advanced ALK-positive non-small cell lung cancer. <i>Cancer Medicine</i> , 2017, 6, 953-961.	1.3	15
63	Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials. <i>Clinical Lung Cancer</i> , 2017, 18, e333-e340.	1.1	14
64	Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw217.	3.0	26
65	The comparison of EGFR-TKI failure modes and subsequent management between exon 19 deletion and exon 21 L858R mutation in advanced non-small-cell lung cancer. <i>Journal of Cancer</i> , 2017, 8, 1865-1871.	1.2	8
66	Development and validation of a nomogram for predicting the survival of patients with non-metastatic nasopharyngeal carcinoma after curative treatment. <i>Chinese Journal of Cancer</i> , 2016, 35, 98.	4.9	32
67	Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. <i>Scientific Reports</i> , 2016, 6, 20090.	1.6	138
68	Pharmacokinetic and Pharmacodynamic Analyses of 5-Fluorouracil in East-Asian Patients with Nasopharyngeal Carcinoma. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1205-1216.	1.6	9
69	Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells <i>In Vitro</i> , <i>In Vivo</i> , and <i>Ex Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1845-1858.	1.9	43
70	Inflammation-based prognostic system predicts postoperative survival of esophageal carcinoma patients with normal preoperative serum carcinoembryonic antigen and squamous cell carcinoma antigen levels. <i>World Journal of Surgical Oncology</i> , 2016, 14, 141.	0.8	14
71	Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: a network metaanalysis. <i>Oncotarget</i> , 2016, 7, 20093-20108.	0.8	31
72	The expression of plakoglobin is a potential prognostic biomarker for patients with surgically resected lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 15274-15287.	0.8	16

#	ARTICLE	IF	CITATIONS
73	Alcohol and survival in ESCC: Prediagnosis alcohol consumption and postoperative survival in lymph node-negative esophageal carcinoma patients. <i>Oncotarget</i> , 2016, 7, 38857-38863.	0.8	15
74	Ratio of C-Reactive Protein/Albumin is An Inflammatory Prognostic Score for Predicting Overall Survival of Patients with Small-cell Lung Cancer. <i>Scientific Reports</i> , 2015, 5, 10481.	1.6	126
75	Advanced Lung Cancer Inflammation Index, a New Prognostic Score, Predicts Outcome in Patients With Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2015, 16, e165-e171.	1.1	60
76	PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival. <i>Oncotarget</i> , 2015, 6, 33019-33032.	0.8	69
77	Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations. <i>PLoS ONE</i> , 2014, 9, e85245.	1.1	125
78	Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials. <i>OncoTargets and Therapy</i> , 2014, 7, 1851.	1.0	15
79	EBV-driven LMP1 and IFN- $\gamma$ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. <i>Oncotarget</i> , 2014, 5, 12189-12202.	0.8	324
80	An investigation of symptom burden and quality of life in Chinese chemo-naïve advanced lung cancer patients by using the Instrument-Cloud QOL System. <i>Lung Cancer</i> , 2014, 84, 301-306.	0.9	12
81	A Large-scale Cross-sectional Study of ALK Rearrangements and EGFR Mutations in Non-small-cell Lung Cancer in Chinese Han Population. <i>Scientific Reports</i> , 2014, 4, 7268.	1.6	28
82	Multi-Targeted Antiangiogenic Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer: Meta-Analyses of 20 Randomized Controlled Trials and Subgroup Analyses. <i>PLoS ONE</i> , 2014, 9, e109757.	1.1	20
83	Predictive Value of High Preoperative Serum Total Protein and Elevated Hematocrit in Patients with Non-Small-Cell Lung Cancer after Radical Resection. <i>Nutrition and Cancer</i> , 0, , 1-13.	0.9	1